Device type · LTJ
Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers
Last checked: Nov 20, 2026Source: openFDAMethods & limitations
Product code
LTJ
Immunology
Device class
Class II
FDA decisions since 2015
2
510(k), De Novo and PMA
Adverse event reports
8
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers
- Product code
- LTJ
- Device class
- Class II
- Review panel
- Immunology
- Regulation
- 21 CFR 866.6010
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for LTJ
Latest FDA decisions
Siemens Healthcare Diagnostics, Inc.
K251630 · Decided Jan 5, 2026 · 222 days after receipt
Device type: Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers (LTJ) · Laboratory Medicine & Pathology
K162378 · Decided May 17, 2017 · 266 days after receipt
Device type: Prostate-Specific Antigen (Psa) For Management Of Prostate Cancers (LTJ) · Laboratory Medicine & Pathology
Reports received
8
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
8
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 3 | 0 | 0 | 0 |
| May 24 | 2 | 0 | 0 | 0 |
| Jun 24 | 1 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 1 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 1 | 0 | 0 | 0 |
| Jan 25 | 1 | 0 | 0 | 0 |
| Feb 25 | 1 | 9 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 1 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 1 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 1 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 3 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 2 | 0 | 0 | 0 |
| Jul 26 | 1 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 1 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Low Test Results7
- High Test Results1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions8
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- PSA TestOpen, Classified
Z-0795-2026 · Started Nov 3, 2025 · Posted by FDA Dec 1, 2025
Reason given: Distribution without premarket approval/clearance.
Cause as FDA categorized it: No Marketing Application
Z-2067-2018 · Started Mar 5, 2018
Reason given: Asfotase Alfa (Strensiq) interferes with certain Tosoh assays which potentially causes falsely increased or falsely decreased immunoassay test results, depending upon the assay.
Cause as FDA categorized it: Device Design
- ADVIA Centaur PSA Assay; Cat No. 06574155/SMN 10310292 (100 test)/02676506/SMN 10310293 (500 test)Terminated
Siemens Healthcare Diagnostics, Inc
Z-2742-2016 · Started Aug 9, 2016
Reason given: Communication provided to emphasize that the PSA values should be interpreted in accordance with current clinical guidelines for defining biochemical recurrence following radical prostatectomy.
Cause as FDA categorized it: Under Investigation by firm
9 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.